...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Evidence-based mental health >Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis.
【24h】

Lack of improvement at week 2 predicts later antipsychotic non-response in people with acute exacerbations of schizophrenia or schizophrenia-like psychosis.

机译：第2周缺乏改善，预示着精神分裂症或精神分裂症样精神病急性加重患者的抗精神病药反应迟钝。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Among the innovative drugs recently introduced for the management of chronic stable angina, Ranolazine and ivabradine represent two most true innovations. In fact, even if both drugs act by reducing myocardial work and thus oxygen consumption, this happens by a peculiar mechanism unlike that of conventional antischemic drugs. Ranolazine mediates its antianginal effects by the inhibition of cardiac late sodium current. This improves myocardial relaxation favoring myocardial perfusion. Ivabradine is a selective Ifchannel blocker and acts by reducing firing rate of pacemaker cells in the sinoatrial node, without affecting the duration of action potential. The reduction of heart rate causes a reduction of left ventricular end diastolic pressure and increases the time useful to coronary flow by a prolongation of the diastole. A body of evidence found that two drugs are useful in ischemic patients whether at rest or during exercise. In addition, they can be used in monotherapy or in association with other conventional anti-ischemic drugs. The two medications could be used with advantage also in microvascular angina when standard therapy is ineffective. Thus, the two drugs represent an adjunctive and powerful therapeutic modality for the treatment of chronic stable angina, especially when conventional antianginal drugs were insufficient or inadequate.
机译：在最近推出的用于治疗慢性稳定型心绞痛的创新药物中，雷诺嗪和伊伐布雷定代表两个最真实的创新。实际上，即使两种药物都通过减少心肌功和氧气消耗而起作用，这也是通过不同于常规抗化学药物的独特机制而发生的。雷诺嗪通过抑制心脏晚期钠电流介导其抗心绞痛作用。这改善了心肌松弛，有利于心肌灌注。伊伐布雷定是一种选择性的If通道阻滞剂，其通过降低窦房结中起搏器细胞的放电速率而起作用，而不影响动作电位的持续时间。心率的降低导致左心室舒张末期压力的降低，并由于舒张期延长而增加了对冠状动脉血流有用的时间。大量证据表明，无论是在休息时还是运动期间，两种药物均可用于缺血患者。另外，它们可以用于单一疗法或与其他常规抗缺血药物联合使用。当标准疗法无效时，这两种药物也可用于微血管性心绞痛。因此，这两种药物代表了用于治疗慢性稳定型心绞痛的辅助且有效的治疗方式，尤其是在常规抗心绞痛药物不足或不足时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号